Link to original article
Left Image: CAT SCan Brain Showing enhancing metastatic lesions from breast-cancer primary. Courtesy of wikimedia commons.
This article explores the work
of Dr. Yamamoto, who discovered the Macrophage-Activating Factor (GcMAF)
in 1990 at the Socrates Institute in Philadelphia (4). Since then, Dr.
Yamamoto has published three human clinical trials showing remarkable
results for breast (5), colo-rectal (10), and prostate cancer(11).
What is MAF -- Macrophage-Activating Factor?
MAF is a protein that activates our
macrophages, the microscopic white cells that kill invading microbes and
cancer cells. MAF is made from a precursor protein called the Gc protein.
Cancer is Clever -- It Inactivates Our Immune System
In a way, cancer cells are clever little devils
because they disable our immune system in order to enhance their own
survival. Dr. Yamamoto discovered that cancer cells do this by
secreting an enzyme called Nagalase, which prevents the precursor protein
Gc from being converted to MAF. This Nagalase-enzyme activity can
actually be measured in cancer patients, and greater tumor burden
corresponds with higher Nagalase enzyme activity (as one would expect).
Elimination of the tumor results in reduction of Nagalase activity to
lower, more normal values. (5)
Dr. Yamamoto devised a technique for restoring
Gc-protein activity, which creates the most potent macrophage-activating
factor ever discovered, having no adverse effects. He called it GcMAF. Macrophages treated in vitro with GcMAF (100 pg/ml) are highly effective at killing breast-cancer cells.
GcMAF for Metastatic Breast Cancer -- Human Trial
Dr. Yamamoto then studied
GcMAF in human metastatic breast-cancer patients with weekly injections
of 100 ng of GcMAF (5). Dr. Yamamoto found that over time, as
treatment with GcMAF progresses, the MAF-precursor activity of patient
Gc protein increased, and the serum Nagalase decreased (5). After 5
months of weekly GcMAF injections, the cancer patients' elevated
Nagalase activity had returned to normal levels, same as healthy
controls. Over the next four years, these sixteen treated metastatic
breast-cancer patients remained cancer free with no recurrence (5). In
2008, Dr. Yamamoto published his landmark study on human breast
GcMAF for Metastatic Colorectal Cancer -- Human Trial
In 2008, Yamamoto published his study
on 8 patients with metastatic colorectal cancer. They all had
significant metastatic disease after primary resection (10). Nagalase
activity fell to normal levels with GcMAF injections, and remained low
with no cancer recurrence over 7 years of observation. This was
supported by serial CAT scans that remained negative.
GcMAF for Metastatic Prostate Cancer -- Human Trial
Dr. Yamamoto studied
in 16 patients with metastatic prostate cancer with excellent results. Nagalase activity declined to normal, and there was no
evidence of tumor recurrence over 7 years of observation. (10)
nonanemic prostate-cancer patients received weekly administration of 100
ng of GcMAF. As the MAF-precursor activity increased, their serum
Nagalase activity decreased. Because serum Nagalase activity is
proportional to tumor burden, the entire time-course analysis for GcMAF
therapy was monitored by measuring the serum Nagalase activity. After 14
to 25 weekly administrations of GcMAF (100 ng/week), all 16 patients
had very low serum Nagalase levels equivalent to those of healthy
control values, indicating that these patients are tumor-free. No
recurrence occurred for 7 years." Quote from abstract of 2008 paper (10).
The Saisei Mirai Clinic in Kobe, Japan
Toshio Inui, MD, of the Saisei Mirai Clinic
in Kobe, Japan, has treated over 345 patients with GcMAF combined with other modalities, and reports his results in Anticancer Research
July 2013 (2,3).
At the Saisei Mirai clinic, Dr. Inui treats
cancer patients with GcMAF immunotherapy in combination with other
related therapies, such as intravenous vitamin C, alpha-lipoic acid,
hyperthermia, and LDN (low-dose naltrexone). Dr Inui says his results are mixed, and
describes his treatment as "hopeful." He presents three cases in which
treatment was remarkably effective:
Patient 1. A 71-year-old man was diagnosed with thymic carcinoma
with lung metastasis. The patient received 24 weeks of the integrative
immunotherapy. No progression of the cancer was found 12 months after
completion of the therapy.
Patient 2. A 74-year-old man was diagnosed with prostate cancer
with multiple bone metastases. He received 12 weeks of the integrative
immunotherapy combined with hyperthermia therapy. Bone scintigram
results nine months after initiation of the therapy were normal and
metastatic tumors had disappeared.
Patient 3. A 72-year-old woman was diagnosed with metastatic
liver cancer after sigmoidectomy and bilateral oophorectomy. She
received 24 weeks of the integrative immunotherapy combined with 55 Gy
of radiation. There was no evidence of local recurrence or metastatic
disease on Positron-Emission Tomography (PET) and Computed Tomography
(CT) scans 12 months after initiation of the therapy.
Next Page 1 | 2 | 3 | 4
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).
Jeffrey Dach MD is a physician and author of three books, Natural Medicine 101, and Bioidentical Hormones 101, and Heart Book all available on Amazon, or as a free e-book on his web sites.
Dr. Dach is founder and chief medical officer of (more...)